Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
(S)-alpha-methyl-4-carboxyphenylglycine is a non-proteinogenic alpha-amino acid and a synthetic analog of alanine, where the alpha-hydrogen is replaced by a 4-carboxyphenyl group. It acts as a non-selective antagonist of group I and group II metabotropic glutamate receptors (mGluRs), thereby inhibiting glutamatergic neurotransmission mediated by these receptor subtypes. This compound is primarily used in research to study the physiological roles of mGluRs in the central nervous system[1][10]. It does not have established therapeutic indications or approved pharmaceutical uses.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on (S)-alpha-methyl-4-carboxyphenylglycine.